1 Endocrine therapy use and the risk of cardiovascular disease in

2 postmenopausal breast cancer survivors: two cohort studies in the

3 UK and US

4 Anthony Matthews, *research fellow* (0000-0002-1290-271X)^{1,2,3}, Sharon Peacock Hinton², *research*

5 *associate*, Susannah Stanway⁴, *consultant in medical oncology*, Alexander R Lyon^{5,6}, *clinical senior*

6 *lecturer*³, Liam Smeeth¹, *professor*, Jennifer L. Lund²*, *assistant professor*, Krishnan Bhaskaran¹*,

7 professor.

8 *Equal contribution

9

¹Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical

11 Medicine, London, WC1E 7HT, UK; ²Department of Epidemiology, Gillings School of Global Public

12 Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; ³Unit of

13 Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden;

⁴Royal Marsden Hospital, London, SW3 6JJ, UK; ⁵National Heart and Lung Institute, Imperial College

15 London, London, SW3 6LY, UK; ⁶Royal Brompton Hospital, London, SW3 6NP, UK.

16

17 Corresponding author: Anthony Matthews: Unit of Epidemiology, Institute of Environmental

18 Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden; <u>anthony.matthews@ki.se</u>; +4670

19 2186973

20 Abstract word count: 310

21 Manuscript word count: 3476

22

1 WHAT THIS PAPER ADDS

2 What is already known on this topic

- 3 It is known that tamoxifen use increases venous thromboembolism risk, but evidence for 4 other cardiovascular outcomes is less clear. Patterns of results are suggestive of a lower risk of coronary heart disease outcomes with 5 • 6 tamoxifen compared to both aromatase inhibitor use and no tamoxifen or placebo, but 7 cardiovascular events are often a secondary consideration and inconsistently reported in 8 trials, and most observational studies use composite cardiovascular definitions, ignoring potentially differential effects on specific cardiovascular outcomes. 9 10 What this study adds Among postmenopausal women with breast cancer, we found an increased risk of several 11 • cardiovascular diseases in aromatase inhibitor compared with tamoxifen users across two 12 13 countries, which appeared to be driven by protective effects of tamoxifen, rather than toxic effects of aromatase inhibitors. We also found the known increased venous 14 15 thromboembolism risk in tamoxifen users. 16 There was no evidence that aromatase inhibitors or tamoxifen increases cardiovascular ٠ 17 disease risk, other than the known increased venous thromboembolism risk with tamoxifen 18 use. However, there was an apparent protective effect of tamoxifen on other cardiovascular 19 outcomes. 20
- 21

1 ABSTRACT

- 2 **Objective:** Examine the effect of tamoxifen and aromatase inhibitors on 12 clinically relevant
- 3 individual cardiovascular outcomes in postmenopausal female breast cancer survivors using large-
- 4 scale datasets from the UK and US.
- 5 **Design:** Two prospective cohort studies
- 6 Setting: Population-based using data from the UK Clinical Practice Datalink linked with Hospital
- 7 Episode Statistics (2002-2016), and the US Surveillance, Epidemiology and End Results-Medicare
- 8 database (2008-2013).
- 9 Participants: 10005 and 22027 postmenopausal women with breast cancer in the UK and US
- 10 respectively.
- 11 **Exposures:** Aromatase inhibitor compared with tamoxifen use; the US cohort additionally included a
- 12 comparison with an "unexposed" group of women with oestrogen or progesterone receptor positive
- 13 breast cancer but no endocrine therapy use.
- Outcomes: 12 clinically relevant individual cardiovascular outcomes (and two composite coronary
 and venous thromboembolic outcomes)
- ,
- 16 **Results:** In both the UK and the US, there was evidence of an increased risk of coronary artery
- disease in aromatase inhibitor compared with tamoxifen users (UK incidence rate: 10.18 vs 6.87 per
- 18 1000 person-years, HR: 1.29, 0.94-1.76; US incidence rate: 35.26 vs 26.95 per 1000 person-years, HR:
- 19 1.29, 1.06-1.55), but the US data showed no increase in risk compared with the unexposed group
- 20 (incidence rate for tamoxifen vs unexposed: 26.95 vs 38.70 per 1000 person-years, HR: 0.74, 0.60-
- 21 0.92; incidence rate for aromatase inhibitors vs unexposed: 35.26 vs 28.70, HR: 0.96, 0.83-1.10).
- 22 Similar patterns were seen for other cardiovascular outcomes such as arrhythmia, heart failure, and
- valvular heart disease. As expected, there were more venous thromboembolic events in tamoxifen
- 24 users compared with both aromatase inhibitor users and those unexposed. There was a high degree
- 25 of consistency between results in the two countries.
- 26 Conclusions: Increased risks of several cardiovascular diseases among aromatase inhibitor compared
- 27 with tamoxifen users appeared to be driven by protective effects of tamoxifen, rather than toxic
- effects of aromatase inhibitors. We also confirmed the known increased risk of venous
- 29 thromboembolic events in tamoxifen users.

1 BACKGROUND

- 2 Breast cancer is the most common cancer among women worldwide; 83% of breast cancer patients
- 3 are diagnosed with oestrogen or progesterone receptor positive disease (ER/PR+) and are
- 4 recommended endocrine therapies to minimise risk of recurrence.[1] Tamoxifen reduces the rate of
- 5 breast cancer recurrence by nearly half, regardless of menopausal status, [2] but since 2006
- 6 aromatase inhibitors (AI) are also recommended to postmenopausal women due to greater efficacy
- 7 over tamoxifen.[3] However, it is hypothesised that these drugs may affect cardiovascular disease
- 8 (CVD) risk through pathways including suppression of protective effects of circulating oestrogen, [4]
- 9 changes in cholesterol, [5, 6] and reduction of antithrombin levels. [7]
- 10
- 11 A recent systematic review collated all evidence for the risk of CVD for users of tamoxifen, AIs, and
- 12 the comparative risk between the two drugs.[8] It suggested that tamoxifen use increases risk of
- 13 venous thromboembolic events, but evidence for other outcomes was less clear. Patterns of results
- 14 are suggestive of a lower risk of coronary heart disease outcomes with tamoxifen compared to both
- 15 Al use and no tamoxifen or placebo, but CVD events are often a secondary consideration and
- 16 inconsistently reported in trials, and most observational studies use composite CVD definitions,
- 17 ignoring potentially differential effects on specific CVDs.
- 18

19 Given the uncertainty and clinical importance, we aimed to examine the effects of tamoxifen and Als

- 20 on 12 clinically relevant individual CVD outcomes (and two composite outcomes) in postmenopausal
- 21 female breast cancer survivors using two large-scale datasets from both the UK and US.
- 22

23 METHODS

24 Study design and data sources

- 25 We assembled two separate and nationally representative cohorts of women with incident
- 26 postmenopausal breast cancer using prospectively collected data from large UK and US electronic
- 27 healthcare databases. In the UK, we used Clinical Practice Research Datalink primary care data (CPRD
- 28 GOLD) and linked Hospital Episode Statistics (HES). [9] In the US, we used the Surveillance,
- 29 Epidemiology, and End Results program (SEER) and Medicare linked database.[10] Full detail on
- 30 these data sources are available in Appendix 1.
- 31

1 Study populations

2 Differences between the study populations were largely driven by differences in data available

3 within the two cohorts, which are fully explained in Appendix 2.

4 <u>UK cohort</u>

5 We identified women with linked CPRD and HES data over 54 years (median age of the menopause

6 in Europe [11]), with incident breast cancer in CPRD (after at least one year of CPRD follow-up), who

7 initiated Als or tamoxifen in primary care after their diagnosis, from 1st January 2002 (date from

8 which preliminary analysis showed that third generation AIs came into widespread use) to 31st

9 March 2016 (latest CPRD and HES linkage). Follow-up began at the latest of one year after breast

10 cancer diagnosis, or first AI or tamoxifen prescription (hereafter index date). Women were excluded

11 if prior to their index date they: died, transferred out of the CPRD, had any other cancer diagnosis, or

12 were diagnosed with the CVD event of interest (at any point prior to index date).

13 <u>US cohort</u>

14 We identified women over 65 years with incident ER/PR+ and stage 1-3 breast cancer and

15 continuous Medicare Parts A, B and D enrolment (and no managed care coverage) for the 12-months

16 prior to the month of cancer diagnosis from 1st January 2008 (Medicare Part D data are available

17 from 2007) and 31st December 2013 (last capture of cancer cases in SEER). Women with an

18 endocrine therapy prescription prior to their breast cancer diagnosis were excluded. Follow up

19 began one year after the date of breast cancer (hereafter index date). Women were excluded if prior

to their index date they: died, discontinued from Medicare Parts A, B, or D, had any other cancer

21 diagnosis, or were diagnosed with the CVD event of interest (within a 3-year look back period to

ensure likelihood of capturing a prior event was not dependent on age as Medicare follow up startsat 65 years).

24

25 Exposure, outcomes, and covariates

26 Tamoxifen and AI exposures were identified using prescription codes in the UK (available at 27 https://doi.org/10.17037/DATA.177), and National Drug Codes (NDCs) and Healthcare Common 28 Procedural Coding System (HCPCS) procedure codes in the US (Appendix 3). The primary exposure 29 was ever use of tamoxifen, ever use of AI, or ever use of both drugs; the US study included an 30 additional category of no exposure to any endocrine therapy (which did not exist in the UK study, 31 because receipt of endocrine therapy was an inclusion criterion). Exposure was time-updated to 32 indicate a woman had been exposed to both drugs if they switched endocrine therapies during 33 follow-up. The baseline exposure group was classified as ever exposure to tamoxifen for the ever AI

1 vs tamoxifen analyses in both the UK and US, whereas the baseline exposure group was changed to 2 no exposure to any endocrine therapy for the ever AI/tamoxifen vs unexposed analyses that were 3 only possible in the US. In secondary analyses, we considered time-updated current exposure to 4 endocrine therapy, categorised as current tamoxifen use, current AI use, no current therapy and 5 prior AI use, no current therapy and prior tamoxifen use only, and (in the US study only) no current 6 or past endocrine therapy. A drug exposure was continuous if a further prescription for the same 7 endocrine therapy followed within 30 days of the end of the previous prescription date plus the days 8 of drug supplied. Further information is in Appendix 4, and visualisations of exposure categorisations 9 in Appendices 5 and 6.

10

11 The main CVD outcomes were: coronary artery disease (angina, myocardial infarction (MI),

12 revascularisation procedures, sudden cardiac arrest (SCA)); peripheral vascular disease (PVD);

13 stroke; arrhythmia; heart failure (HF, including cardiomyopathy); pericarditis, valvular heart disease

14 (VHD); and venous thromboembolism (VTE) (deep vein thrombosis (DVT), pulmonary embolism

15 (PE)). Composite CVD outcomes and individual components of the composite outcomes were

16 analysed separately. Events were identified through clinical diagnoses using NHS Read codes in the

17 CPRD and International Classification of Disease (ICD), 10th edition codes in HES in the UK (available

18 at https://doi.org/10.17037/DATA.177), and ICD-9 and Healthcare Common Procedure Coding

19 System (HCPCS) codes in the US study (Appendix 7).

20

21 In both studies, we adjusted for age, cardiovascular history and risk factors, use of cardio-protective 22 medications, other comorbidities, time since index date, and calendar year. In the UK we were 23 additionally able to adjust for smoking, alcohol use, body mass index, and index of multiple 24 deprivation (a measure of socioeconomic status); in the US study we were additionally able to adjust 25 for race, region and use of anti-cancer therapies. A full comparison of the covariates considered in 26 the UK and US is in Appendix 8. Algorithms to define confounders in the UK are in Appendix 9, and 27 code lists used for variable definitions are at https://doi.org/10.17037/DATA.177. Codes used to 28 identify prescriptions in the US are in Appendix 10.

29

30 Statistical Analysis

31 Observation time began at index date and ended at the earliest of: a CVD event of interest; diagnosis

32 of another (non-breast) cancer; death; transfer out of CPRD/end of Medicare Parts A, B, or D

enrolment; or end of study period (31st March 2016 in UK which is the last available CPRD collection

date, and 31st December 2014 in US which is the last available Medicare collection date).

2

3 Separate analyses were conducted in UK and US data. Distributions of baseline characteristics of 4 patients at index date were described. Number of events and crude incident rates of each outcome 5 of interest by exposure were calculated. Cox proportional hazards regression models with an 6 underlying age timescale were fitted for each outcome of interest to obtain unadjusted hazard ratios 7 (HRs) and 95% CIs for the association between endocrine therapy use and outcome; those with a 8 diagnosis of the specific outcome of interest before the index date were excluded from the analysis 9 for that outcome. All covariates were then added to obtain fully-adjusted HRs and 95% CIs. The 10 analysis was repeated for the primary and secondary exposure definitions. Using the primary 11 exposure definitions in each country, we then fitted interactions to investigate effect modification by 12 current age (54-69, 70+ in the UK; 66-84, 85+ in the US); time since index date (0-1 years, 1-3 years, 13 3+ years); and history of any CVD prior to index date for the coronary artery disease (composite), 14 arrhythmia, stroke, pericarditis (US only), heart failure, VHD, and VTE (composite) outcomes 15 (interactions were not investigated for other outcomes due to limited power). Women with missing 16 data (8.7% in the UK, and 5.1% in the US) were excluded from all analyses (complete case analysis),

17 which is valid in a regression context if missingness is conditionally independent of the outcome.[12]

18

19 Sensitivity analyses

To ensure comparability between the UK and US, the main analyses were repeated with the study populations and covariates modified to be as similar as possible. Further details in Appendix 11. Furthermore, in case of misclassification of exposure, the grace period used to define a continuous prescription was extended from 30 days to 3 months, 6 months, and 1 year in the analyses of current endocrine therapy exposure. Finally, a post-hoc quantitative bias analysis explored potential unmeasured confounding in the large estimated protective effect of tamoxifen use on the risk of MI (Appendix 12).[13]

27

28 Patients and the public were not involved at any point during this research.

29

30 **RESULTS**

The UK study included 10005 women, with 4716 (47%) initially prescribed tamoxifen and 5289 (53%)

32 initially prescribed an AI (Table 1, flow diagram in Figure 1). Mean follow-up from index date for

1 individual CVD outcomes ranged from 4-4.1 years. The US study included 22027 women, with 4667

2 (22%), 2286 (10%) and 15074 (68%) initially filling no endocrine therapy, tamoxifen, and an Al

3 respectively (Table 2, flow diagram in Figure 1). Mean follow-up from index date for individual CVD

- 4 outcomes ranged from 2.3-2.5 years.
- 5

6 Ever Exposure analyses

7 Ever Al vs Tamoxifen use

8 In both the UK and US settings, there was a higher observed rate of most CVDs, excluding VTE

9 outcomes, among those ever exposed to an AI compared with tamoxifen (Appendices 13-14). In

adjusted analyses, there was strong evidence of a higher risk of heart failure in AI compared with

11 tamoxifen users in the UK (HR: 1.68, 1.24-2.26, Figure 2), which was not replicated in the US (HR:

12 0.96, 0.83-1.12). Other adjusted HRs were consistent between the two settings; there was evidence

13 in one or both settings that AI users compared with tamoxifen users had higher risk of coronary

14 artery disease, myocardial infarction, arrhythmia, pericarditis, and VHD (HRs ranged from 1.29-3.25

15 in the UK, and 1.21-1.81 in the US, Figure 2) and lower risk of deep vein thrombosis (UK HR: 0.63,

16 0.43-0.93; US HR: 0.81, 0.50-1.09).

17

18 Ever Al/Tamoxifen use vs unexposed

19 The US study included women without exposure to either endocrine therapy; observed rates of most 20 CVDs, excluding VTE, were lower in both the tamoxifen and AI groups compared with the unexposed 21 group, while VTE outcome rates were higher in the endocrine therapy groups (Appendix 14). The 22 patterns were similar in adjusted analyses (Figure 3); there was evidence that tamoxifen users had 23 lower risks than unexposed women for coronary artery disease, myocardial infarction, stroke, 24 arrhythmia, pericarditis, and VHD (HRs ranged from 0.37-0.87); HR point estimates for AI users vs 25 unexposed were also in the protective direction for all non-VTE CVD outcomes, but in most cases 26 were closer to the null than for tamoxifen, and with confidence intervals including no association. 27 There was weak evidence of higher risk VTE in tamoxifen users compared with the unexposed (HR: 28 1.39, 0.98-1.98), but little evidence of a difference for AI users vs unexposed (HR: 1.14, 0.86-1.52). 29 30 Current exposure analyses

Results for the analysis of current endocrine therapy use were consistent with the findings in the
primary ever exposure analyses, and were consistent between the UK and US (Appendices 15-18).
33

34 Effect modification

1	There was no strong evidence of effect modification by age, time since index date, or prior CVD in
2	the UK or US (Appendices 19-20), though there were few events within strata, limiting precision.
3	There was a suggestion in UK data that the raised risk of coronary artery disease in AI compared with
4	tamoxifen users diminished over time (p=0.02), but no corresponding evidence in US data.
5	
6	Sensitivity analyses
7	Following modification of study populations, methodology, and covariates in the UK and US to make
8	them as similar as possible, the risk of all CVDs associated with ever and current AI compared to
9	tamoxifen use were generally in the same direction, albeit with less precision in UK data (Appendices
10	21-22). However, the discrepant results for heart failure between the two cohorts persisted.
11	
12	Altering the grace period used to define continuous drug use had little effect on results (Appendices
13	23-24).
14	
15	Quantitative bias analyses suggest that unmeasured confounding was unlikely to fully explain the
16	large HR for the effect of ever tamoxifen use on the risk of MI (Appendix 25).

17

18 DISCUSSION

These two population-based cohort studies using UK and US data are the first to apply similar 19 20 methodology to two large populations to assess the effects of endocrine therapies on a range of CVD outcomes in postmenopausal women with breast cancer. Both countries' results suggested a higher 21 22 risk of several CVD outcomes in AI compared with tamoxifen users, with no evidence that any other 23 characteristics, including previous CVD, modified the estimated effect. However, comparisons with 24 women exposed to neither drug suggest that this is driven by a decreased risk of these CVD 25 outcomes in tamoxifen users; and there was no evidence for any cardiotoxicities associated with AI 26 use compared with those unexposed to endocrine therapy. In both the UK and the US, tamoxifen 27 users were consistently at higher risk of VTE outcomes than both AI users and those unexposed to 28 endocrine therapy.

29

The protective effect of tamoxifen on some CVDs might be explained by the drug's effect on lipid levels. Previous studies have found tamoxifen to reduce total serum cholesterol (10-15%) and lowdensity lipoprotein cholesterol (15-22%).[5, 6] It has also been suggested that AIs could increase the risk of CVD compared with tamoxifen through depleting oestrogen-mediated protective CVD

1 effects, [4] but several trials have compared hypercholesterolemia between AI and tamoxifen users,

- 2 with inconclusive results.[14-16]
- 3

4 Comparison to other studies

5 A recent meta-analysis of trials reported an increased risk of a composite CVD outcome, excluding

- 6 VTE, in tamoxifen compared with AI users (RR: 1.18, 1.05-1.33),[17] with results suggestive of a
- 7 cardio-protective effect of tamoxifen, consistent with the results of this study.
- 8

9 Several studies have focused on more specific CVD outcomes, and MI, stroke, heart failure, and VTE 10 are the outcomes with the largest body of previous evidence, but there is little evidence for the 11 other specific CVD outcomes that we explored. Most (4/5) previous studies directly comparing the 12 risk of MI in AI and tamoxifen users have reported an increased risk in AI users, similar to our results 13 (RRs ranged from 0.99-2.02).[18-22] Two previous trials and five observational studies have 14 compared MI risk in tamoxifen users with non-use/placebo, with 4/7 studies finding a reduced risk in 15 tamoxifen users (RRs ranged from 0.20-0.83);[23-29] two analogous studies of AI use versus placebo 16 or non-use found no association. [16, 28] Six studies (five trials and one observational) directly 17 compared the risk of stroke in AI and tamoxifen users, but associations in both directions have been 18 reported. [20, 22, 30-33] Three out of five studies (one trial and four observational) comparing 19 tamoxifen use with non-use/placebo found a protective association with stroke, as in our study (RRs 20 ranged from 0.52-0.81).[23, 26-28, 34] In the present analysis, we found AI users to be at reduced 21 risk of stroke compared to unexposed women; one previous study found a similar association but a 22 second reported the opposite.[16, 28]. Two previous studies (one trial and one observational) have 23 reported results for the comparison between AI and tamoxifen use on the risk of heart failure, [30, 24 33] for which we reported discrepant results between the UK and US. One reported an increased risk 25 in AI users and the other reported no association. The discrepant results in our study could be due to 26 residual confounding by variables not available in both datasets (cancer therapies in the UK, and 27 lifestyle factors in the US), or the nature of the data sources (routinely collected records in the UK 28 and claims in the US).

29

30 Six previous trials compared the risk of VTE in AI and tamoxifen users, with five reporting a

31 decreased risk in AI compared with tamoxifen users (RR ranged from 1.25-0.61), as reported in both

32 UK and US data in this study. [18, 20, 22, 30, 35, 36] Six out of eight studies (five trials and three

33 observational) also reported an effect estimate that suggested an increased risk in tamoxifen users

34 (RRs ranged from 1.64-7.10), which is in the same direction, but larger than the effect in US data

1 here. One observational study reported an increased risk of VTE in Al users (RR: 1.84, 1.11-3.04), but

2 US data suggested no association.

3

4 Strengths and limitations

5 A major strength of this study was the use of two large data sources from different countries, with 6 complementary strengths and different limitations. By including data from study populations with 7 different characteristics, we could look for consistency in observed associations, and conduct 8 different comparisons, notably between classes, and with unexposed patients. We were also able to 9 assess the relationships between endocrine therapy treatments and a wide range of CVD outcomes, 10 rather than the composite and individual CVD outcomes in many previous studies. We were also 11 able to account for several important confounders such as potentially cardio-toxic treatments 12 (anthracyclines and trastuzumab, in US data) and lifestyle factors (BMI, smoking, and alcohol, in UK 13 data); although no confounders materially changed the crude effect estimate when adjusted for 14 individually in the ever exposure analyses in either the UK or US (Appendices 26 and 27). As the 15 CPRD broadly represents the UK population, and SEER-Medicare includes a large, diverse population 16 of older women diagnosed with breast cancer, results are generalisable to women diagnosed with 17 ER/PR+ breast cancer in both the UK, US, and other developed populations due to the homogenous 18 indication of endocrine therapy worldwide.

19

20 In the UK, ER/PR status was not available, but it is likely that breast cancers were ER/PR+ as such a 21 diagnosis is a prerequisite of being prescribed endocrine therapies. The unavailability of ER/PR status 22 also meant that we could not identify a group of untreated patients diagnosed with ER/PR+ breast 23 cancer in the UK. Furthermore, CPRD captures prescriptions at the point of issue, but we do not 24 know if prescriptions were filled, which could lead to potential misclassification of exposure. 25 However, descriptive analyses using a 6 month grace period to define a continuous prescription 26 indicated that 97% of women continued to be prescribed within 1 year of starting, 95% within 3 27 years, and 85% within 5 years.

28

In the US, the relatively high proportion of non-initiators of endocrine therapy (21%) in women with ER/PR+ was similar to the proportion of non-initiators reported in a previous study.[17] Reasons for non-initiation may include frailty, poor CVD preventative care, and high BMI, introducing possible residual confounding, especially given lack of information on smoking and BMI in US data. Although quantitative bias analyses suggest it is unlikely that residual confounding explains all of the large observed protective associations between tamoxifen use and several CVD outcomes, these

1 associations may have been exaggerated, and the smaller observed associations between AI use and

2 outcomes could be driven by such confounding. Comparisons to non-user groups are often more

3 subject to confounding than comparisons to groups utilizing similar medications (i.e. Al vs

4 tamoxifen).[37] Some caution should be taken in the interpretation of the comparisons with non-

- 5 users, and these results warrant further investigation.
- 6

7 Implications

- 8 Our results indicated no excess cardiotoxicities of endocrine therapy, other than the raised risk of
- 9 VTE with tamoxifen. There was no evidence of raised risk of any CVD with AI use, including in
- 10 stratified results restricted to those with prior CVD, suggesting that a history of cardiovascular
- disease should not be a contraindication for prescription of an AI. It is likely that AIs will continue to
- 12 be the preferred endocrine therapy of choice in postmenopausal survivors of ER/PR+ breast cancer
- 13 given its superior efficacy over tamoxifen. However, in women at a high CVD risk, it would be
- 14 informative to know if any cardio-protective effects of tamoxifen might offset the superior reduction
- 15 in risk of breast cancer recurrence with AIs. Further knowledge of the risk-benefit balance of the two
- 16 endocrine therapies in terms of effects on cancer survival and cardiovascular outcomes in sub-
- 17 groups of women would help guide individual-level prescribing decisions.
- 18

19 CONCLUSION

20 Among postmenopausal women diagnosed with ER/PR+ breast cancer, we found convincing

21 evidence of increased risks of several CVDs in AI compared with tamoxifen users. However, these

- associations appeared to be driven by protective effects of tamoxifen, rather than any toxic effects
- of AIs. There was no evidence that either drug type causally increased the risks of CVD outcomes,
- other than the known increased VTE risk with tamoxifen use. This information will help to inform
- and better understand the risk-benefit balance of these widely used endocrine therapies.

1 FOOTNOTES

The corresponding author has the right to grant on behalf of all authors and does grant on behalf of
all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis
to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions
and any other BMJPGL products and sub-licenses such use and exploit all subsidiary rights, as set out
in our license.
Conflicts of interest
AM, SPH, and JL have nothing to disclose. SS reports personal fees from Roche, Clinigen, Eli Lilly, and

10 Novartis, outside the submitted work. AL reports personal fees from Servier, Novartis, Pfizer, Roche,

11 Ferring Pharmaceuticals, Clinigen Group, Boehringer Ingelheim, Amgen, Eli Lily, and BMS, outside

12 the submitted work. LS reports grants from Wellcome, during the conduct of the study; grants from

13 Wellcome, MRC, NIHR, BHF, Diabetes UK, and grants and personal fees from GSK, outside the

submitted work; and Is a trustee of the British Heart Foundation. KB reports grants from Wellcome

15 Trust and the Royal Society, during the conduct of the study.

16

17 Contributions

18 Study designs were decided on by AM, JL, and KB. AM and SPH carried out data extraction. AM

19 carried out all analyses. AM wrote the first draft. All authors contributed to further drafts and

20 approved the final manuscript.

21

22 Funding

23 This study was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and

the Royal Society (grant No 107731/Z/15/Z) held by KB. The Wellcome Trust and the Royal Society
had no role in the design, analysis, or writing up of this study.

26 Ethical approval

27 The UK study was approved by the ethics board at the London School of Hygiene and Tropical

28 Medicine (project ID: 12025), and the US study was gained IRB approval at the University of North

29 Carolina (study number: 17-1766)

30

31 Data sharing

32 Data from either the UK or US studies are not openly accessible, but can be gained through an

33 application to the CRPD and SEER-Medicare respectively.

1 Transparency

- 2 The lead author affirms that the manuscript is an honest, accurate, and transparent account of the
- 3 study being reported; that no important aspects of the study have been omitted; and that any
- 4 discrepancies from the study as planned (and, if relevant, registered) have been explained.

5

1 **REFERENCES**

2	1.	Howlader, N., et al., US incidence of breast cancer subtypes defined by joint hormone
3		receptor and HER2 status. J Natl Cancer Inst, 2014. 106 (5).
4	2.	Early Breast Cancer Trialists' Collaborative, G., et al., Relevance of breast cancer hormone
5		receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis
6		<i>of randomised trials</i> . Lancet, 2011. 378 (9793): p. 771-84.
7	3.	Dowsett, M., et al., Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase
8		inhibitors versus tamoxifen. J Clin Oncol, 2010. 28 (3): p. 509-18.
9	4.	Mendelsohn, M.E. and R.H. Karas, The protective effects of estrogen on the cardiovascular
10		system. N Engl J Med, 1999. 340 (23): p. 1801-11.
11	5.	Dewar, J.A., et al., Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ,
12		1992. 305 (6847): p. 225-6.
13	6.	Love, R.R., et al., Effects of tamoxifen on cardiovascular risk factors in postmenopausal
14		women after 5 years of treatment. Journal of the National Cancer Institute, 1994. 86(20): p.
15		1534-9.
16	7.	Love, R.R., T.S. Surawicz, and E.C. Williams, Antithrombin III level, fibrinogen level, and
17		platelet count changes with adjuvant tamoxifen therapy. Archives of Internal Medicine,
18		1992. 152 (2): p. 317-20.
19	8.	Matthews, A., et al., Long term adjuvant endocrine therapy and risk of cardiovascular disease
20	01	in female breast cancer survivors: systematic review. BMJ, 2018. 363 : p. k3845.
21	9.	Herrett, E., et al., <i>Data Resource Profile: Clinical Practice Research Datalink (CPRD).</i> Int J
22	5.	Epidemiol, 2015. 44 (3): p. 827-36.
23	10.	Warren, J.L., et al., Overview of the SEER-Medicare data: content, research applications, and
24	10.	generalizability to the United States elderly population. Med Care, 2002. 40 (8 Suppl): p. IV-3-
25		
26	11.	Dratva, J., et al., Is age at menopause increasing across Europe? Results on age at
20 27	11.	menopause and determinants from two population-based studies. Menopause, 2009. 16 (2):
28		p. 385-94.
29	12.	White, I.R. and J.B. Carlin, <i>Bias and efficiency of multiple imputation compared with</i>
30	12.	complete-case analysis for missing covariate values. Stat Med, 2010. 29 (28): p. 2920-31.
31	13.	Lash, T.F., MP. Fink, AK., Applying Quantitative Bias Analysis to Epidemiologic Data. 2009:
32	10.	Springer.
33	14.	Arimidex, T.A.o.i.C.T.G., et al., <i>Comprehensive side-effect profile of anastrozole and</i>
34		tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of
35		<i>the ATAC trial.</i> Lancet Oncol, 2006. 7 (8): p. 633-43.
36	15.	Coates, A.S., et al., Five years of letrozole compared with tamoxifen as initial adjuvant
37		therapy for postmenopausal women with endocrine-responsive early breast cancer: update
38		of study BIG 1-98. Journal of Clinical Oncology, 2007. 25 (5): p. 486-92.
39	16.	Goss, P.E., et al., Randomized trial of letrozole following tamoxifen as extended adjuvant
40		therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal
41		of the National Cancer Institute, 2005. 97 (17): p. 1262-71.
42	17.	Khosrow-Khavar, F., et al., Cardiotoxicity of aromatase inhibitors and tamoxifen in
43	±7.	postmenopausal women with breast cancer: a systematic review and meta-analysis of
43 44		randomized controlled trials. Ann Oncol, 2017. 28 (3): p. 487-496.
44 45	18.	Jakesz, R., et al., Switching of postmenopausal women with endocrine-responsive early
45 46	10.	breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG
40 47		trial 8 and ARNO 95 trial. Lancet, 2005. 366 (9484): p. 455-62.
47 48	19.	Coombes, R.C., et al., Survival and safety of exemestane versus tamoxifen after 2-3 years'
40 49	тэ.	tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet,
49 50		2007. 369 (9561): p. 559-70.
50		2007. 303 (3301). p. 333-70.

1	20.	Pagani, O., et al., Adjuvant exemestane with ovarian suppression in premenopausal breast
2		<i>cancer.</i> N Engl J Med, 2014. 371 (2): p. 107-18.
3	21.	Abdel-Qadir, H., et al., The risk of myocardial infarction with aromatase inhibitors relative to
4		tamoxifen in post-menopausal women with early stage breast cancer. Eur J Cancer, 2016. 68 :
5	22	
6	22.	Arimidex, T.A.o.i.C.T.G., et al., <i>Effect of anastrozole and tamoxifen as adjuvant treatment for</i>
7		early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology, 2008. 9 (1):
8	22	p. 45-53. McDanald, C.C., et al., Cardina and unanylar markidity in warran reaciving adjuvant.
9 10	23.	McDonald, C.C., et al., <i>Cardiac and vascular morbidity in women receiving adjuvant</i>
10		tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ, 1995. 311 (7011): p. 977-80.
12	24.	Rutqvist, L.E., Long-term toxicity of tamoxifen. Recent Results in Cancer Research, 1993. 127 :
13	24.	p. 257-66.
14	25.	Bradbury, B.D., et al., Tamoxifen-treated breast carcinoma patients and the risk of acute
15	23.	myocardial infarction and newly-diagnosed angina. Cancer, 2005. 103 (6): p. 1114-21.
16	26.	Yang, T.L., et al., Association of tamoxifen use and reduced cardiovascular events among
17		asian females with breast cancer. Circulation Journal, 2014. 78 (1): p. 135-40.
18	27.	Hernandez, R.K., et al., Tamoxifen treatment in Danish breast cancer patients and 5-year risk
19		of arterial atherosclerotic events: a null association. Cancer Epidemiology, Biomarkers &
20		Prevention, 2008. 17 (9): p. 2509-11.
21	28.	Ligibel, J.A., et al., Risk of myocardial infarction, stroke, and fracture in a cohort of
22		community-based breast cancer patients. Breast Cancer Research & Treatment, 2012.
23		131 (2): p. 589-97.
24	29.	Geiger, A.M., W. Chen, and L. Bernstein, Myocardial infarction risk and tamoxifen therapy for
25		<i>breast cancer</i> . British Journal of Cancer, 2005. 92 (9): p. 1614-20.
26	30.	Colleoni, M., et al., Analyses adjusting for selective crossover show improved overall survival
27		with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol, 2011.
28		29 (9): p. 1117-24.
29	31.	Abo-Touk, N.A., H.A. Sakr, and A. Abd El-Lattef, Switching to letrozole versus continued
30 21		tamoxifen therapy in treatment of postmenopausal women with early breast cancer. J Egypt
31 22	22	Natl Canc Inst, 2010. 22 (1): p. 79-85.
32 33	32.	Kaufmann, M., et al., Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued
34		tamoxifen: the ARNO 95 Study. J Clin Oncol, 2007. 25 (19): p. 2664-70.
35	33.	Haque, R., et al., <i>Cardiovascular Disease After Aromatase Inhibitor Use</i> . JAMA Oncol, 2016.
36	34.	Geiger, A.M., et al., Stroke risk and tamoxifen therapy for breast cancer. Journal of the
37	51.	National Cancer Institute, 2004. 96 (20): p. 1528-36.
38	35.	Boccardo, F., et al., Switching to anastrozole versus continued tamoxifen treatment of early
39		breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol,
40		2006. 17 Suppl 7 : p. vii10-4.
41	36.	Bliss, J.M., et al., Disease-related outcomes with long-term follow-up: an updated analysis of
42		the intergroup exemestane study. J Clin Oncol, 2012. 30 (7): p. 709-17.
43	37.	Schneeweiss, S., et al., Increasing levels of restriction in pharmacoepidemiologic database
44		studies of elderly and comparison with randomized trial results. Med Care, 2007. 45 (10 Supl
45		2): p. S131-42.
10		

Table 1 - Characteristics of study population based on their

1 initial exposure in the UK Tamoxifen AI Total 10005 (100) Ν 2 4716 (100) 5289 (100) Age (yrs) 911 (19.3) 54-59 716 (13.5) 1627 (16.3) 3 60-69 1850 (39.2) 1955 (41.5) 1972 (37.3) 3822 (38.2) 70+ 2601 (49.2) 4556 (45.5) Median (IQR) 69 (62-78) 68 (62-76) 70 (63-79) 4 Year of breast cancer 2002 579 (12.3) 72 (1.4) 651 (6.5) 2003 605 (12.8) 123 (2.3) 728 (7.3) 5 2004 571 (12.1) 186 (3.5) 757 (7.6) 2005 512 (10.9) 289 (5.5) 801 (8) 6 2006 467 (9.9) 370 (7) 837 (8.4) 2007 386 (8.2) 448 (8.5) 834 (8.3) 2008 380 (8.1) 495 (9.4) 875 (8.7) 7 2009 290 (6.1) 533 (10.1) 823 (8.2) 2010 223 (4.7) 586 (11.1) 809 (8.1) 2011 216 (4.6) 619 (11.7) 835 (8.3) 8 2012 210 (4.5) 539 (10.2) 749 (7.5) 2013 174 (3.7) 504 (9.5) 678 (6.8) 9 2014 93 (2) 451 (8.5) 544 (5.4) 2015 10 (.2) 74 (1.4) 84 (.8) BMI (kg/m2) 10 59 (1.3) 63 (1.2) 122 (1.2) <18 1693 (35.9) 1619 (30.6) 3312 (33.1) 18-24 1549 (32.8) 1801 (34.1) 3350 (33.5) 25-29 11 800 (17) 1779 (17.8) 30-34 979 (18.5) ≥35 345 (7.3) 548 (10.4) 893 (8.9) 12 Missing 270 (5.7) 279 (5.3) 549 (5.5) Median (IQR) 26 (23-30) 27 (24-31) 27 (24-31) Smoking status 13 2423 (51.4) 2517 (47.6) 4940 (49.4) Never smoker Currentsmoker 503 (10.7) 482 (9.1) 985 (9.8) 1761 (37.3) 2268 (42.9) 4029 (40.3) 14 Ex-s moker Missing 29 (.6) 22 (.4) 51 (.5) Alcohol use 15 618 (13.1) 613 (11.6) 1231 (12.3) Non drinker 3320 (70.4) 3628 (68.6) 6948 (69.4) Current Ex-drinker 480 (10.2) 715 (13.5) 1195 (11.9) 16 Missing 298 (6.3) 333 (6.3) 631 (6.3) Systolic BP 599 (11.3) Low/ideal 530 (11.2) 1129 (11.3) 17 Pre-high 1862 (39.5) 2327 (44) 4189 (41.9) 2314 (49.1) 2355 (44.5) 4669 (46.7) High 18 Missing 10 (.2) 8 (.2) 18 (.2) Diastolic BP 2650 (50.1) 2130 (45.2) 4780 (47.8) Low/ideal 19 4046 (40.4) Pre-high 1988 (42.2) 2058 (38.9) High 588 (12.5) 573 (10.8) 1161 (11.6) 20 Missing 10 (.2) 8 (.2) 18 (.2) IMD category 870 (18.4) 962 (18.2) 1 1832(18.3) 21 2 943 (20) 1214 (23) 2157 (21.6) 3 925 (19.6) 1054 (19.9) 1979 (19.8) 4 1052 (22.3) 936 (17.7) 1988 (19.9) 22 5 926 (19.6) 1122 (21.2) 2048 (20.5) Missing 0 (0) 1 (0) 1 (0) 23 CVD related treatment before index Statins 1100 (23.3) 1903 (36) 3003 (30) 1195 (25.3) 1823 (34.5) 3018 (30.2) ACEI 24 CCB 1195 (25.3) 1764 (33.4) 2959 (29.6) ARB 493 (10.5) 795 (15) 1288 (12.9) Anti-platelets 1132(24) 1639 (31) 2771 (27.7) 25 Comorbidities before index RA 138 (2.9) 137 (2.6) 275 (2.7) 26 Diabetes 462 (9.8) 728 (13.8) 1190 (11.9) CKD 867 (18.4) 1090 (20.6) 1957 (19.6) CVD before index 27 1031 (21.9) 1636 (30.9) 2667 (26.7) Non-venous CVD VTE before index 324 (6.1) 144 (3.1) 468 (4.7)

28

29

Table 2 - Characteristics of study population based on their initial

exposure in the US

	Unexposed	Tamoxifen	AI	Total
N	4667 (100)	2286 (100)	15074 (100)	22027 (100)
Age at index date (yrs)				
66-74	1538 (33)	897 (39.2)	7505 (49.8)	9940 (45.1)
75-84	1937 (41.5)	994 (43.5)	5894 (39.1)	8825 (40.1)
85+	1192 (25.5)	395 (17.3)	1675 (11.1)	3262 (14.8)
Median (IQR)	79 (73-85)	77 (72-83)	75 (71-81)	76 (71-82)
Ethnicity		•		
White	4002 (85.8)	2028 (88.7)	12782(84.8)	18812(85.4)
Black	360 (7.7)	102 (4.5)	1099 (7.3)	1561 (7.1)
Other	93 (2)	47 (2.1)	335 (2.2)	475 (2.2)
Asian	123 (2.6)	68 (3)	498 (3.3)	689 (3.1)
Hispanic				397 (1.8)
Native American	-	_	-	52 (.2)
Missing	-	_	-	41 (.2)
SEER Region				++ \·+/
North East	760 (16.3)	283 (12.4)	3320 (22)	4363 (19.8)
South				. ,
North Central	1023 (21.9) 695 (14.9)	605 (26.5) 448 (19.6)	3778 (25.1) 1761 (11.7)	5406 (24.5) 2904 (13.2)
West				2904 (13.2)
	2157 (46.2)	939 (41.1)	6130 (40.7)	9226 (41.9)
Missing	32 (.7)	11 (.5)	85 (.6)	128 (.6)
Year of breast cancer	047/10 1)	414 (10 1)	2075 (12.0)	2226 /15 4)
2008	847 (18.1)	414 (18.1)	2075 (13.8)	3336 (15.1)
2009	831 (17.8)	449 (19.6)	2140 (14.2)	3420 (15.5)
2010	729 (15.6)	368 (16.1)	2394 (15.9)	3491 (15.8)
2011	744 (15.9)	333 (14.6)	2625 (17.4)	3702 (16.8)
2012	756 (16.2)	350 (15.3)	2709 (18)	3815 (17.3)
2013	760 (16.3)	372 (16.3)	3131 (20.8)	4263 (19.4)
Stage of breast cancer				
Stagel	3034 (65)	1486 (65)	8379 (55.6)	12899 (58.6)
Stage II	1275 (27.3)	660 (28.9)	5267 (34.9)	7202 (32.7)
Stage III	358 (7.7)	140 (6.1)	1428 (9.5)	1926 (8.7)
Grade of breast cancer				
1	1522 (32.6)	765 (33.5)	4273 (28.3)	6560 (29.8)
2	2071 (44.4)	1109 (48.5)	7350 (48.8)	10530 (47.8)
3	853 (18.3)	324 (14.2)	2810 (18.6)	3987 (18.1)
Missing	221 (4.7)	88 (3.8)	641 (4.3)	950 (4.3)
Cancer treatments				
Taxane	570 (12.2)	162 (7.1)	2415 (16)	3147 (14.3)
Anthracyclines	259 (5.5)	68 (3)	820 (5.4)	1147 (5.2)
Trastuzumab	226 (4.8)	39 (1.7)	687 (4.6)	952 (4.3)
Other treatment	753 (16.1)	244 (10.7)	2992 (19.8)	3989 (18.1)
Comorbidities	\/	/	/	()
RA	185 (4)	103 (4.5)	547 (3.6)	835 (3.8)
CKD	383 (8.2)	155 (6.8)	1113 (7.4)	1651 (7.5)
Hypertension	3426 (73.4)	1612 (70.5)	1113 (73.7)	16151 (73.3)
Diabetes				
	1313 (28.1)	598 (26.2)	4545 (30.2)	6456 (29.3)
CVD related treatment before index	1770 (20.1)	049 (41 5)	CO00 / 4C 4)	0714/444
Statins	1778 (38.1)	948 (41.5)	6988 (46.4)	9714 (44.1)
Hypertensives	169 (3.6)	83 (3.6)	577 (3.8)	829 (3.8)
ACEI	962 (20.6)	477 (20.9)	3251 (21.6)	4690 (21.3)
CCB	850 (18.2)	364 (15.9)	2696 (17.9)	3910 (17.8)
ARB	593 (12.7)	255 (11.2)	2063 (13.7)	2911 (13.2)
Past CVD				
Non venous CVD	2989 (64)	1281 (56)	8896 (59)	13166(59.8)
VTE	162 (3.5)	31 (1.4)	385 (2.6)	578 (2.6)

1 FIGURE LEGENDS

2 Figure 1 - Flow diagrams of study populations in the UK and US


3

- 4 Figure 2 Adjusted HRs for the association between ever AI use compared with ever tamoxifen use
- 5 and the risk of a range of clinical CVD outcomes in the UK and US


- 7 Figure 3 Adjusted HRs, events, and crude rate per 1000 person-years for the association between
- 8 ever exposure to endocrine therapy and a range of clinical CVD outcomes in the US

UK flow diagram

US flow diagram




Not stage 1-3 breast cancer = 5613 Endocrine therapy prescription before breast cancer diagnosis = 15 Diagnosis of another cancer between breast cancer diagnosis and index = 13



Hazard Ratio (95% CI)

* UK results adjusted for the following covariates at baseline: for age (54-59, 60-69, 70+); smoking status (non-smoker, current smoker, ex-smoker); BMI (underweight/healthy weight, overweight, obese); alcohol status (non-drinker, current drinker, ex-drinker); IMD score (level 1-5 based on GP level IMD data); use of statins; use of ACE inhibitors; use of calcium channel blockers (CCB); use of angiotensin II receptor blockers (ARB); diabetes; chronic kidney disease; rheumatoid arthritis; systolic blood pressure (low/normal, pre-high, high); history of VTE; history of non-venous CVD year of breast cancer diagnosis; time since index (0-1yrs, 1-3yrs, 3-5yrs, 5+yrs); and current year.

US results adjusted for year of breast cancer diagnosis (2007-2013); age at index date (66-74, 75-84, 85+); race (White, Black Asian, Hispanic, Native American, other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (0-1yr, 1-3yrs, 3-5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD



Hazard Ratio (95% CI)

* Adjusted for year of breast cancer diagnosis (2007-2013); age at index date (66-74, 75-45, 85+); race (White, Black Asian, Hispanic, Native American, other); SEER region (North East, South, North Central, West); breast cancer stage (1-3); breast cancer grade (1-3); time since index date (0-1yr, 1-3yrs, 3-5yrs, 5+yrs); current calendar year; use of taxanes, anthracyclines, trastuzumab, other systemic cancer treatments, statins, anti-hypertensive drugs, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers; diagnosis of rheumatoid arthritis, chronic kidney disease, hypertension, diabetes, VTE, and non-venous CVD ** Events and follow-up supressed if number of events ≤ 11